Table 2 Summary of findings 1: biological treatments compared to placebo for Psoriatic Arthritis—ACR50
Summary of findings | ||||||
|---|---|---|---|---|---|---|
Biological treatment effects to ACR 50 outcome (6-month follow-up) in the treatment of Psoriatic Arthritis patients | ||||||
Population: Psoriatic Arthritis patients Intervention: Biological treatments (Adalimumab, Etanercept, Infliximab, Golimumab, Secukinumab, Certolizumab pegol) and synthetic target-specific drugs (Tofacitinib) Comparator (reference): Placebo |
| |||||
Biological treatments | Anticipated absolute effect* (95% CI) | Relative effect (95% CI) | No of participants (studies) | Certainty of evidence (GRADE) | Ranking | |
Without intervention | With intervention | |||||
Secukinumab | 8 per 100 | 32 per 100 (22–46) | RR 4.13 (2.87–5.94) | 2535 (7 RCTs) | ⨁⨁⨁⨁ High | 1º - P-score = 0.77 |
Infliximab | 12 per 100 | 44 per 100 (22–88) | RR 3.79 (1.87–7.68) | 403 (3 RCTs) | ⨁◯◯◯ Very low | 2º - P-score = 0.66 |
Adalimumab | 13 per 100 | 46 per 100 (32–67) | RR 3.58 (2.47–5.19) | 1957 (7 RCTs) | ⨁⨁⨁⨁ High | 3º - P-score = 0.62 |
Certolizumab pegol | 13 per 100 | 42 per 100 (17–100) | RR 3.37 (1.34–8.49) | 409 (1 RCT) | ⨁⨁◯◯ Low | 4º - P-score = 0.57 |
Golimumab | 12 per 100 | 38 per 100 (20–71) | RR 3.15 (1.68–5.90) | 347 (3 RCTs) | ⨁⨁⨁⨁ High | 5º - P-score = 0.51 |
Tofacitinib | 12 per 100 | 38 per 100 (21–71) | RR 3.11 (1.67–5.77) | 472 (2 RCTs) | ⨁⨁⨁◯ Moderate | 6º - P-score = 0.49 |
Etanercept | 24 per 100 | 65 per 100 (34–100) | RR 2.71 (1.42–5.18) | 623 (3 RCTs) | ⨁⨁⨁◯ Moderate | 7º - P-score = 0.39 |
Placebo | – | – | Reference comparator | – | – | – |
